NCT04720534 Phase 2 Completed
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia Study sponsor: Arrowhead Pharmaceuticals
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2023-03-09 Actual
Enrollment · participants 229 Actual
Source updated 2026-03-24 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
Posted 2026-03-24 · 1 field changed
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before Measure: Percent Change from Baseline in Fasting Triglycerides (TG) at Week 24
+ After Measure: Percent Change From Baseline at Week 24 in Fasting Triglycerides (TG)
Check registry source
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial